Functional, cognitive and behavioral benefits of donepezil inpatients with moderate Alzheimer's disease.

被引：0
|
作者：
Feldman, H
Gauthier, S
Hecker, J
Vellas, B
Emir, B
Subbiah, P
机构：
[1] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada
[2] McGill Ctr Studies Aging, Verdun, PQ, Canada
[3] Repatriat Gen Hosp, Daw Pk, Australia
[4] Toulouse Univ, Alzheimers Ctr, Toulouse, France
[5] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2002年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
P286
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [41] Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials
    Passmore, AP
    Bayer, AJ
    Steinhagen-Thiessen, E
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 229 : 141 - 146
  • [42] Benefits of donepezil on global function, behavior, cognition, and ADLs in patients with moderate-to-severe Alzheimer's disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Subbiah, P
    Whalen, E
    NEUROLOGY, 2000, 54 (07) : A469 - A469
  • [43] Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer’s disease
    Drugs & Therapy Perspectives, 2011, 27 (4) : 9 - 12
  • [44] Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease
    Waldemar, Gunhild
    Gauthier, Serge
    Jones, Roy
    Wilkinson, David
    Cummingss, Jeffrey
    Lopez, Oscar
    Zhang, Richard
    Xu, Yikang
    Sun, Yijun
    Knox, Sean
    Richardson, Sharon
    Mackell, Joan
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2011, 26 (02) : 150 - 157
  • [45] The association of non-cognitive symptoms and functional impairment in Alzheimer's disease.
    Yee, MW
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : S42 - S42
  • [46] Cognitive-behavioral treatment for depressed patients with Alzheimer's disease. An open trial
    Maria Garcia-Alberca, Jose
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2017, 71 : 1 - 8
  • [47] FACTORS IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE.
    Luppi, C.
    Fioravanti, M.
    Bertolini, B.
    Inguscio, M.
    Grugnetti, A.
    Guerriero, F.
    Rovelli, C.
    Cantoni, F.
    Guagnano, P.
    Marazzi, E.
    Rolfo, E.
    Ghianda, D.
    Levante, D.
    Bonacasa, R.
    Solerte, S. B.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2009, 21 (01) : 88 - 88
  • [48] Management of cognitive deficits in Alzheimer's disease.
    Van der Linden, M
    Juillerat, AC
    REVUE NEUROLOGIQUE, 1998, 154 : S137 - S143
  • [49] Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Ieni, J
    Xu, Y
    Schwam, E
    NEUROLOGY, 2005, 64 (06) : A105 - A105
  • [50] Possible benefits of valproate addition to donepezil treatment in Alzheimer's disease
    Borkowska, A.
    Tomaszewska, M.
    Wilkosc, M.
    Drozdz, W.
    Cichosz, A.
    Rybakowski, J. K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S478 - S478
12345